Amneal Pharmaceuticals, Inc.AMRXNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank75
3Y CAGR+44.3%
5Y CAGR+27.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+44.3%/yr
Quarterly compound
5Y CAGR
+27.2%/yr
Recent acceleration
Percentile
P75
Within normal range
vs 5Y Ago
3.3x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 6.27% |
| Q3 2025 | 10.90% |
| Q2 2025 | 5.05% |
| Q1 2025 | -8.08% |
| Q4 2024 | 8.42% |
| Q3 2024 | 1.91% |
| Q2 2024 | 3.43% |
| Q1 2024 | 3.30% |
| Q4 2023 | -3.54% |
| Q3 2023 | 7.04% |
| Q2 2023 | 3.40% |
| Q1 2023 | -0.06% |
| Q4 2022 | 2.09% |
| Q3 2022 | 1.28% |
| Q2 2022 | 0.14% |
| Q1 2022 | 1.48% |
| Q4 2021 | 6.38% |
| Q3 2021 | 6.08% |
| Q2 2021 | -5.04% |
| Q1 2021 | 7.13% |
| Q4 2020 | 1.89% |
| Q3 2020 | 2.69% |
| Q2 2020 | 3.81% |
| Q1 2020 | 5.25% |
| Q4 2019 | 16.12% |
| Q3 2019 | -5.18% |
| Q2 2019 | -20.32% |
| Q1 2019 | 18.53% |
| Q4 2018 | -8.76% |
| Q3 2018 | 47.30% |
| Q2 2018 | 110.99% |
| Q1 2018 | -6.84% |
| Q4 2017 | -1.73% |
| Q3 2017 | 1.86% |
| Q2 2017 | -2.76% |
| Q1 2017 | -11.00% |
| Q4 2016 | 0.00% |